CRISPR Therapeutics AG (CRSP) Other Non-Current Liabilities (2015 - 2026)

CRISPR Therapeutics AG (CRSP) has 12 years of Other Non-Current Liabilities data on file, last reported at $5.9 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 79.16% year-over-year to $5.9 million; the trailing twelve-month figure through Mar 2026 stood at $5.9 million (up 79.16% YoY), and the FY2025 full-year result was $6.1 million, up 78.34% from the prior year.
• Other Non-Current Liabilities eased to $5.9 million in Q1 2026, from $6.1 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $7.3 million in Q1 2022 to a low of $958000.0 in Q4 2023.
• A 5-year average of $4.8 million and a median of $5.3 million in 2022 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities tumbled 83.95% in 2023 and jumped 259.5% in 2024, its largest moves.
• Tracing CRSP's Other Non-Current Liabilities over 5 years: stood at $6.0 million in 2022, then plunged by 83.95% to $958000.0 in 2023, then jumped by 259.5% to $3.4 million in 2024, then surged by 78.34% to $6.1 million in 2025, then fell by 3.16% to $5.9 million in 2026.
• Business Quant data shows CRSP's Other Non-Current Liabilities at $5.9 million in Q1 2026, $6.1 million in Q4 2025, and $5.3 million in Q3 2025.